BACKGROUND AND AIMS: Many studies have been published that report an association between thymidylate synthase (TS) and response to fluoropyrimidine-based chemotherapy and the overall outcome of patients with gastrointestinal cancer. The results have given rise to the possibility that, by determination of TS levels, the physician may decide if the patient has a potential benefit from fluoropyrimidine-based treatment, similar to measurements of oestrogen receptors in breast cancer. The purpose of this review is to summarize critically the reports on TS measurement in gastrointestinal cancer, focusing on the adjuvant fluoropyrimidine treatment situation. METHODS: We reviewed more than 20 studies that reported the association of TS with the clinical outcome in patients with gastrointestinal cancer who had undergone complete resection of the primary tumour only or were receiving additional adjuvant chemotherapy. RESULTS: Patients with metastasized disease who expressed high TS levels display a low probability of responding to fluoropyrimidine-based treatment and have a poorer survival rate. Patients with high TS levels who undergo complete surgical resection of the primary tumour also have a poorer prognosis than those with tumours with low TS expression. In contrast to advanced disease and to surgery alone, patients with high TS levels appear to benefit, especially, from adjuvant fluoropyrimidine-based chemotherapy after complete primary tumour resection, while patients with low TS levels do not. CONCLUSION: Patients with gastrointestinal cancers that express high TS levels have a poor prognosis with regard to fluoropyrimidine-based palliative chemotherapy or complete primary tumour resection. In contrast, patients with high TS levels might benefit from adjuvant fluoropyrimidine-based treatment after primary tumour resection. However, additional prospective studies are mandatory to define the precise role of TS in adjuvant therapy.
BACKGROUND AND AIMS: Many studies have been published that report an association between thymidylate synthase (TS) and response to fluoropyrimidine-based chemotherapy and the overall outcome of patients with gastrointestinal cancer. The results have given rise to the possibility that, by determination of TS levels, the physician may decide if the patient has a potential benefit from fluoropyrimidine-based treatment, similar to measurements of oestrogen receptors in breast cancer. The purpose of this review is to summarize critically the reports on TS measurement in gastrointestinal cancer, focusing on the adjuvant fluoropyrimidine treatment situation. METHODS: We reviewed more than 20 studies that reported the association of TS with the clinical outcome in patients with gastrointestinal cancer who had undergone complete resection of the primary tumour only or were receiving additional adjuvant chemotherapy. RESULTS:Patients with metastasized disease who expressed high TS levels display a low probability of responding to fluoropyrimidine-based treatment and have a poorer survival rate. Patients with high TS levels who undergo complete surgical resection of the primary tumour also have a poorer prognosis than those with tumours with low TS expression. In contrast to advanced disease and to surgery alone, patients with high TS levels appear to benefit, especially, from adjuvant fluoropyrimidine-based chemotherapy after complete primary tumour resection, while patients with low TS levels do not. CONCLUSION:Patients with gastrointestinal cancers that express high TS levels have a poor prognosis with regard to fluoropyrimidine-based palliative chemotherapy or complete primary tumour resection. In contrast, patients with high TS levels might benefit from adjuvant fluoropyrimidine-based treatment after primary tumour resection. However, additional prospective studies are mandatory to define the precise role of TS in adjuvant therapy.
Authors: M Kornmann; K H Link; H J Lenz; J Pillasch; R Metzger; U Butzer; G H Leder; M Weindel; F Safi; K D Danenberg; H G Beger; P V Danenberg Journal: Cancer Lett Date: 1997-09-16 Impact factor: 8.679
Authors: A Tomiak; M Vincent; C C Earle; P G Johnston; W Kocha; M Taylor; J Maroun; L Eidus; F Whiston; L Stitt Journal: Am J Clin Oncol Date: 2001-12 Impact factor: 2.339
Authors: Carmen J Allegra; Allyson L Parr; Lester E Wold; Michelle R Mahoney; Daniel J Sargent; Patrick Johnston; Pam Klein; Katie Behan; Michael J O'Connell; Ralph Levitt; John W Kugler; Maria Tria Tirona; Richard M Goldberg Journal: J Clin Oncol Date: 2002-04-01 Impact factor: 44.544
Authors: T Takenoue; H Nagawa; K Matsuda; S Fujii; M E Nita; K Hatano; J Kitayama; T Tsuruo; T Muto Journal: Ann Surg Oncol Date: 2000-04 Impact factor: 5.344
Authors: D Edler; U Kressner; P Ragnhammar; P G Johnston; I Magnusson; B Glimelius; L Påhlman; G Lindmark; H Blomgren Journal: Clin Cancer Res Date: 2000-02 Impact factor: 12.531
Authors: James C Yao; Paul F Mansfield; Peter W T Pisters; Barry W Feig; Nora A Janjan; Christopher Crane; Jaffer A Ajani Journal: Semin Surg Oncol Date: 2003
Authors: A Paradiso; G Simone; S Petroni; B Leone; C Vallejo; J Lacava; A Romero; M Machiavelli; M De Lena; C J Allegra; P G Johnston Journal: Br J Cancer Date: 2000-02 Impact factor: 7.640
Authors: J Choi; H Lim; D K Nam; H S Kim; D Y Cho; J W Yi; H C Kim; Y K Cho; M W Kim; H J Joo; K B Lee; K B Kim Journal: Br J Cancer Date: 2001-01 Impact factor: 7.640
Authors: Karl-Heinz Link; Marko Kornmann; Ludger Staib; Martin Redenbacher; Martina Kron; Hans Günter Beger Journal: Ann Surg Date: 2005-08 Impact factor: 12.969
Authors: Bo Song; Yuan Wang; Matthew A Titmus; Galina Botchkina; Andrea Formentini; Marko Kornmann; Jingfang Ju Journal: Mol Cancer Date: 2010-04-30 Impact factor: 27.401
Authors: Uffe H Olesen; Jakob G Petersen; Antje Garten; Wieland Kiess; Jun Yoshino; Shin-Ichiro Imai; Mette K Christensen; Peter Fristrup; Annemette V Thougaard; Fredrik Björkling; Peter B Jensen; Søren J Nielsen; Maxwell Sehested Journal: BMC Cancer Date: 2010-12-12 Impact factor: 4.430
Authors: Christoph Burdelski; Christian Strauss; Maria Christina Tsourlakis; Martina Kluth; Claudia Hube-Magg; Nathaniel Melling; Patrick Lebok; Sarah Minner; Christina Koop; Markus Graefen; Hans Heinzer; Corinna Wittmer; Till Krech; Guido Sauter; Waldemar Wilczak; Ronald Simon; Thorsten Schlomm; Stefan Steurer Journal: Oncotarget Date: 2015-04-10